Skip to main content

Advertisement

SpringerLink
Log in

New treatments for superficial bladder cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The successful treatment of bladder cancer remains a challenge for urologists and oncologists. Substantial changes have been made in the therapeutic options for the management of superficial bladder cancer in the past 5 years. We review the preclinical and clinical developments over the past year in bladder cancer therapeutics. A growing trend involves the use of multimodality treatments for all bladder cancers. For superficial disease, intravesical instillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard of care. Novel therapeutic modalities under investigation include DNA vaccines, magnetically targeted carriers, bioadhesive microspheres, and antisense oligodeoxynucleotides. Treatment goals for superficial bladder cancer are complete removal of the initial tumor, prevention of disease recurrence, and inhibition of progression to invasive disease. The myriad novel therapeutic modalities under exploration suggest that these goals may be achievable within our lifetime.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. National Cancer Institute Surveillance, Epidemiology, and End Results Cancer Statistics Review. http://seer. cancer.gov/csr/1975_2002/results_merged/sect_27_urinary_ bladder.pdf Accessed February 13, 2006.

  2. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10–30.

    Article  PubMed  Google Scholar 

  3. Lamm DL, Blumenstein BA, Crissman JD, et al.:Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncolog y Group Study. J Urol 2000, 163:1124–1129.

    Article  PubMed  CAS  Google Scholar 

  4. Witjes JA: Management of BCG failures in superficial bladder cancer: A review. Eur Urol 2006 Jan 24; [Epub ahead of print].

  5. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. and EORTC Genito-Urinary Tract Cancer Group: Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003, 44:429–434.

    Article  PubMed  Google Scholar 

  6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. and EORTC Genito-Urinary Tract Cancer Group: The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003, 44:423–428.

    Article  PubMed  Google Scholar 

  7. O’Donnell MA, Krohn J, De Wolf WC: Salvage intravesical therapy with interferon-alpha2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001, 166:1300–1305.

    Article  PubMed  CAS  Google Scholar 

  8. Belldegrun AS, Franklin JR, O’Donnell MA, et al.: Super-ficial bladder cancer: the role of interferon-alpha. J Urol 1998, 159:1793–1801.

    Article  PubMed  CAS  Google Scholar 

  9. Kalble T, Beer M, Mendoza E, et al.: BCG vs. interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 1994, 33:133–137.

    PubMed  CAS  Google Scholar 

  10. O’Donnell MA, Luo Y, Hunter SE, et al.: Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 2004, 171:1330–1335. Interesting study of the therapeutic effects of IL-12 in a murine bladder cancer model.

    Article  PubMed  CAS  Google Scholar 

  11. Lee C, Chang S, Hsieh D, Yu D: Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol 2004, 171:1343–1347. A comprehensive analysis of the possible role for DNA vaccines in the treatment of bladder cancer.

    Article  PubMed  CAS  Google Scholar 

  12. Dalbagni G, Mazumdar M, Russo P, et al.: Phase II trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder [abstract]. J Urol 2004, 171(4S):72-A274. First trial showing efficacy of gemcitabine as an intravesical instillation agent. Abstract presented at 2004 American Urological Association meeting in San Francisco.

    Google Scholar 

  13. Leakakos T, Cheng J, Lawson G, et al.: Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003, 51:445–450. A pilot study in a non-cancer model showing the potential for magnetically targeted carriers to be used intravesically.

    PubMed  CAS  Google Scholar 

  14. Nativ O, Aronson M, Medalia O, et al.: Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 1997, 70:297–301.

    Article  PubMed  CAS  Google Scholar 

  15. Le Visage C, Rioux-Leclercq N, Haller M, et al.: Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004, 171:1324–1329. An innovative idea aimed at improving the efficiency of intravesical paclitaxel delivery. May also have applicability to other intravesical agents in the future.

    Article  PubMed  CAS  Google Scholar 

  16. Miyake H, Eto H, Hara I, et al.: Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeox ynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer koTCC-1 cells. J Urol 2004, 171:2477–2481. A well-designed and thoroughly-executed study looking at the utility of antisense oligodeoxynucleotides to inhibit clusterin expression and potentiate gemcitabine cytotoxicity.

    Article  PubMed  CAS  Google Scholar 

  17. Miyake H, Nelson C, Rennie PS, and Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res 2000, 60:2547–2554.

    PubMed  CAS  Google Scholar 

  18. Zellweger T, Miyake H, July LV, et al.: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001, 3:360–367.

    Article  PubMed  CAS  Google Scholar 

  19. Fuessel S, Kueppers B, Ning S, et al.: Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004, 171:2471–2476. Early in vitro analysis of survivin as another potential target for antisense oligodeoxynucleotides.

    Article  PubMed  CAS  Google Scholar 

  20. Gakiopoulou H, Nakopoulou L, Siatelis A, et al.: Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003, 9:5573–5581.

    PubMed  CAS  Google Scholar 

  21. Koga F, Kageyama Y, Kawakami S, et al.: Prognostic significance of endothelial Per-Arnt-Sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 2004, 171:1080–1084.

    Article  PubMed  CAS  Google Scholar 

  22. Malkowicz SB: Management of superficial bladder cancer. In Campbell’s Urology, vol 4, edn 8. Edited by Walsh P, Retik AB, Vaughan ED, Wein AJ. New York: Saunders, 2002:2797.

    Google Scholar 

  23. French AJ, Datta SN, Allman R, Matthews PN: Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. BJU Int 2004, 93:156–161. Early in vitro analysis of survivin as another potential target for antisense oligodeoxynucleotides.

    Article  PubMed  CAS  Google Scholar 

  24. Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C: Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 2004, 72:284–291.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Columbia University Medical Center, Herbert Irving Pavilion, 11th Floor, 161 Fort Washington Avenue, 10032, New York, NY, USA

    James M. McKiernan MD

Authors
  1. Jay B. Shah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gina M. Badalato BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James M. McKiernan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. McKiernan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, J.B., Badalato, G.M. & McKiernan, J.M. New treatments for superficial bladder cancer. Curr Oncol Rep 8, 201–205 (2006). https://doi.org/10.1007/s11912-006-0020-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0020-x

Keywords

Search

Navigation